Trial Profile
Efficacy and Safety Study of Pegasys plus lamivudin Vs lamivudine alone in the Treatment of Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Sep 2020
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary) ; Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 24 Sep 2020 Results published in the Internet Document
- 12 Sep 2020 Results (n=83) of retrospective NCT00048945 and other study evaluating Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B, published in the Journal of Hepatology
- 18 May 2018 New trial record